A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer

PURPOSE. For patients with metastatic colorectal cancer (mCRC), no standard therapy exists after progression on 5-fluorouracil, oxaliplatin, irinotecan, bevacizumab, and cetuximab or panitumumab. Preclinical data demonstrated that combined vascular endothelial growth factor and mammalian target of r...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Altomare, Ivy, Bendell, Johanna C., Bullock, Karen E., Uronis, Hope E., Morse, Michael A., Hsu, S. David, Zafar, S. Yousuf, Blobe, Gerard C., Pang, Herbert, Honeycutt, Wanda, Sutton, Linda, Hurwitz, Herbert I.
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2011
Témata:
Gastrointestinal Cancer
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3228156/
https://ncbi.nlm.nih.gov/pubmed/21795432
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0078
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky